IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies

Cancer Clinical Trial Compensation: Undue or Long Overdue?

Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

New IASLC Grading System for Pulmonary Adenocarcinoma Proposed

Acute Admissions Rates for Lung Cancer Patients Up During Pandemic, Not Linked to COVID-19

Modeling Analyses Show That Expansions in Lung Cancer Screening Guidelines to Better Capture Underrepresented Populations Still Need Work

Young Investigators Awarded Grants to Study COVID-19 and Lung Cancer

Lung Ambition Alliance: Stronger Together 

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Patient Advocate Comment: Amivantamab for Exon 20

Presidential Symposium Findings 

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC